A 25-year-old immunology concept became 2024's most-hyped skincare buzzword. One molecule was crowned "15× more effective than niacinamide." We followed the evidence trail.
In autumn 2024, a $88 face serum arrived in the beauty press with an unusual pitch: it didn't promise to reverse wrinkles or fill lines. It promised to interrupt inflammaging — chronic, low-grade inflammation described as the "root cause of skin aging."
The ingredient at the centre was naringenin, a molecule from grapefruit peel, produced through bio-fermentation. The brand — Deinde, backed by biotech firm Debut and $71 million in funding led by L'Oréal — cited a lab number that was hard to ignore: "15× more effective than niacinamide."
By mid-2025, the serum had won an industry award. By early 2026, the price had quietly dropped to $68.
Three questions were left unanswered by the marketing:
We treated each as a separate line of inquiry.
The term didn't originate in a beauty lab. It was coined in 2000 by Claudio Franceschi, an Italian immunologist studying centenarians at the University of Bologna.
Franceschi's original hypothesis: as bodies age, they accumulate low-level inflammatory signals — cytokines like IL-6, TNF-α, IL-1β — even without any active infection or disease. This background inflammation, he argued, was itself a driver of age-related decline, from cardiovascular disease to neurodegeneration.
The concept turned out to be productive science. In the 25 years since, thousands of peer-reviewed papers have investigated inflammaging in cardiovascular medicine, neurology, metabolic disease, and — most relevant here — dermatology.
What research since 2020 has established about skin inflammaging:
So the underlying biology is real. Chronic low-grade inflammation in aging skin is not marketing invention — it's an active area of dermatological research.
But there's a gap between "real biological phenomenon" and "a serum can fix it."
Inflammaging in the original literature is systemic — it's about macrophages, senescent cells throughout the body, immune remodeling over decades. Skin inflammaging is a subset. And whether a topical cream can meaningfully redirect that process is a separate question from whether inflammaging exists.
Verdict on Line 1: the concept is not fabricated. It has a legitimate 25-year research lineage. What's new is not the science — it's the marketing translation.
Naringenin is a flavonoid — specifically, a flavanone — naturally present in citrus fruits, most concentrated in grapefruit peel. Its chemical structure and behaviour have been studied since well before any skincare brand licensed it.
We looked for peer-reviewed research on naringenin's effects on skin that was published independently — before Deinde existed, funded by academic or government sources, and not tied to any brand.
Four studies, four different labs, four different countries, all published between 2016 and 2024 — none affiliated with Debut Biotech or Deinde:
Study 1 — Brazil, PLOS ONE 2016 Researchers at Universidade Estadual de Londrina formulated topical naringenin (95% purity from a chemical supplier) into a stable cream and tested it on hairless mice exposed to UVB radiation. Result: skin swelling, oxidative damage, and inflammatory markers all reduced. Mice, not humans, but the topical delivery worked.
Study 2 — J Cell Mol Med 2016 A separate group demonstrated that naringenin binds directly to ERK2 (a signalling enzyme) and blocks the UVB-induced production of MMP-1 — one of the key collagen-degrading enzymes in skin. The study used both cell cultures and mice.
Study 3 — Biomedical Dermatology 2018 Researchers using human dermal fibroblasts (the cells that make collagen) showed naringenin activates SIRT1, blocks NF-κB inflammation signalling, and reduces MMP expression at a cellular level. Their conclusion: "naringenin can be used as an effective cosmetic ingredient." This was written six years before Deinde's launch.
Study 4 — Cosmetics MDPI 2023 A team at Amway R&D tested naringenin against both UVB and air pollution exposure in human skin cells and reconstructed epidermis. Naringenin suppressed MMP-1, MMP-3, IL-6, and GM-CSF. It also reduced pigmentation-related genes and, on pigmented reconstructed epidermis, decreased melanin production.
Study 5 — Frontiers in Chemistry 2024 (arguably the most rigorous comparison) Researchers at Universidade de São Paulo compared four polyphenols — naringenin, chlorogenic acid, apigenin, kaempferol — in identical 0.1% topical gels. They tested skin irritation (all four passed) and, critically, protection against UV-induced lipid peroxidation in the stratum corneum. Naringenin was the only one of the four to show significant anti-oxidative protection. The other three actually behaved as pro-oxidants under UV stress.
What this consistent independent record tells us:
There is genuine, non-brand-affiliated evidence that naringenin has meaningful biological activity on skin cells — anti-inflammatory, anti-oxidative, MMP-suppressing, UVB-protective. Multiple mechanisms, replicated across labs, across years, across species.
What it doesn't tell us — and this matters:
Every one of these five studies is either in-vitro (cells, reconstructed skin models) or on animals (hairless mice). Not one is a randomised controlled trial on human faces.
That's not a criticism of the researchers — early ingredient science almost always starts this way. But it means the evidence base for naringenin's visible cosmetic effect on human skin — wrinkles, elasticity, "healthier appearance" — rests on a single source: the brand selling the product.
This is the number that sold the serum. It appears in press coverage, on the product page, and in the founder's explanation of why naringenin matters.
Traced to its source, the claim is based on cell-culture experiments comparing single inflammation biomarkers (primarily IL-6) at what Debut describes as "recommended active levels" — 0.45% naringenin versus higher percentages of niacinamide.
Three things worth understanding about this number:
First — it's an in-vitro comparison, not a clinical one. No human faces used one product versus the other. The comparison is: cells exposed to inflammatory stress, treated with naringenin, versus cells treated with niacinamide, measuring how much a single inflammatory cytokine went down.
Second — it's a single-biomarker measurement. Niacinamide's real-world cosmetic effect draws on multiple pathways — barrier support, pigmentation regulation, sebum control, hydration. A test focused on one biomarker doesn't capture what niacinamide is actually valued for. It's like comparing two cars by measuring only how loud their engines are.
Third — the concentrations weren't matched. The "15×" figure comes from comparing naringenin at its intended in-product concentration against niacinamide at concentrations meant to test a different mechanism. If you compared them at identical concentrations, or if you compared their end-effects on skin appearance rather than one biomarker, you'd get a different number — possibly a very different one.
None of this makes the underlying test dishonest. Debut's team, to their credit, discloses the methodology in their marketing footnotes. What it makes the number is not what a shopper thinks it means. A shopper hears "15× more effective" and imagines the product would take 15× fewer weeks to visibly work than niacinamide. That comparison hasn't been made.
The brand's own 8-week clinical study — 30 participants, placebo-controlled, in-house — reported: 100% of participants showed improved moisture and elasticity, 97% showed reduction in fine lines. These are the results actually attributable to the finished product.
Two things to note about that study:
Independent replication doesn't yet exist.
Inflammaging as a scientific concept: legitimate, 25 years of research, well-supported.
Naringenin as a topical ingredient: genuinely active biologically — the independent evidence for its mechanism is real, and it appears to have properties (barrier-related anti-oxidative protection, MMP suppression) that some other popular polyphenols don't share.
Naringenin as a specifically anti-aging product: the leap from cell-culture and mouse studies to visible human anti-aging results is currently supported by one in-house clinical study of 30 people. That's a promising start, not proof.
"15× stronger than niacinamide": a cell-culture measurement of one biomarker at unmatched concentrations. Not a head-to-head clinical comparison.
By our grading standards — where Grade A requires multiple independent human RCTs with consistent effect sizes, and Grade B requires strong mechanism plus at least one clinical study — naringenin sits currently at Grade B. Strong independent mechanism, respectable early clinical work, no independent replication yet on humans.
Which is not nothing. But it's not "15× more effective than niacinamide," either.
Setting aside the marketing arithmetic, the evidence pattern suggests naringenin may be most useful in specific situations:
It's telling that consumer reviews for the Deinde serum — the most-visible naringenin product on the market — cluster around a specific demographic: women aged 40-55 in perimenopause, particularly those whose skin had become intolerant of tretinoin. That's not the "zillennials" the marketing targets. It's a group finding real, if narrower, value than the "reverses aging" positioning suggests.
Yes — as a biological phenomenon. The term describes chronic, low-grade inflammation that accumulates with age, first defined by Italian immunologist Claudio Franceschi in 2000. Twenty-five years of peer-reviewed research support the concept in cardiovascular, neurological, and dermatological contexts. What's new is the marketing translation of the concept into a skincare buzzword — not the underlying science.
There is genuine independent evidence, published between 2016 and 2024 by researchers unaffiliated with any skincare brand, that naringenin has anti-inflammatory, anti-oxidative, and MMP-suppressing activity in skin cells and animal models. However, all independent research is either in-vitro (cell cultures, reconstructed epidermis) or on animals. The one clinical study on human faces was conducted by the brand selling the product, with 30 participants over 8 weeks. That's a promising early signal, not established proof of visible anti-aging effects.
That claim comes from a cell-culture comparison of a single inflammatory biomarker (IL-6) at unmatched concentrations, not from a head-to-head clinical trial on human faces. Niacinamide's real-world cosmetic value draws on multiple pathways — barrier, pigmentation, sebum, hydration — that a single-biomarker test doesn't capture. The number is technically defensible in its narrow context but doesn't mean naringenin outperforms niacinamide as a skincare ingredient by a factor of 15.
Based on the mechanism (anti-inflammatory, anti-oxidative) and the pattern in consumer reviews, naringenin appears best-suited to sensitive or reactive skin, perimenopausal skin where potent retinoids are poorly tolerated, and as a complement to collagen-building actives rather than a replacement for them. It's not a strong candidate for aggressive collagen regeneration on younger, resilient skin.
Debut Biotech holds patents on their biotech-fermented naringenin, which they've made exclusive to Deinde. Naringenin from plant extraction is available in other cosmetic products at varying purity and concentration — the ingredient itself isn't proprietary, only Debut's specific bio-fermented version. If independent brands begin releasing plant-extracted naringenin serums with clinical studies, the evidence base will strengthen quickly. Currently, one high-purity biotech source and multiple lower-purity plant-extracted alternatives coexist.
This article grades ingredient claims for appearance and comfort purposes only. Nothing here is medical advice or a treatment recommendation. We do not sell naringenin — it is exclusively formulated into the Deinde product line by Debut Biotech. Our grade reflects the current state of independent evidence, not a comparative product review.
A credentialed reviewer (PharmD / PhD / MD) will be named before this entry is finalised. Until then, treat it as a working draft. Last updated 7 July 2026.
A neutral reference and a lawful-lane shop. Registered in Spain. Information for those who seek it — never promotion.
This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia SL — Registered in Spain.